Table 3 Multivariate analysis of risk factors for secondary glaucoma in eyes with VKH disease
From: Risk factors for secondary Glaucoma in patients with Vogt-Koyanagi-Harada disease
Risk Factor | Non-glaucoma (n = 78)a | Glaucoma (n = 16)b | Relative Risk (95% CI) | p Valuec |
|---|---|---|---|---|
Oral prednisone > 24 months | 24 (30.8) | 12 (85.7) | 9.33 (2.21–39.28) | < 0.001 |
Topical steroids > 12 months | 26 (33.3) | 10 (71.4) | 3.88 (1.31–11.46) | 0.007 |
Anterior chamber cells ≥2+ | 37 (47.4) | 11 (78.6) | 3.36 (1.003–11.26) | 0.032 |
≥2 recurrences | 26 (33.3) | 12 (85.7) | 8.52 (2.02–35.92) | < 0.001 |
Chronic-recurrent stage | 13 (16.7) | 6 (42.9) | 2.88 (1.11–12.63) | 0.037 |
Angle-closure | 14 (18.9) | 10 (71.4) | 7.08 (2.44–20.48) | < 0.001 |
Iris bombé | 6 (7.7) | 6 (42.9) | 5.00 (2.10–11.90) | 0.002 |
Peripapillary atrophy | 10 (12.8) | 6 (42.9) | 3.56 (1.43–8.85) | 0.014 |